natgillin/translations-raw huggingface dataset:
Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis for the Clinician´s interview based impression of change” (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; Severe impairment battery (SIB): p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer’s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis for the Clinician´s interview based impression of change” (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; Severe impairment battery (SIB): p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician’s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer’s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis for the Clinician´s interview based impression of change” (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; Severe impairment battery (SIB): p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician’s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer’s disease cooperative study – activities of the daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis” for Clinician's interview based impression of change (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; SIB: p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis” for Clinician's interview based impression of change (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; SIB: p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician’s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study- activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis” for Clinician's interview based impression of change (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; SIB: p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician’s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer’s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis” for clinician's interview based impression of change (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; SIB: p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p = 0.025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p = 0.003; severe impairment battery (SIB): p = 0.002).
Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis” for Clinician´s interview based impression of change (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; Severe impairment battery (SIB): p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Undersøgelsen viste ingen signifikante forskelle mellem Resolor og placebo for nogen af doserne på grundlag af gennemsnitlige QT-målinger og analyse af afvigende værdier.
This study did not show significant differences between Resolorand placebo at either dose, based on mean QT measurements and outlier analysis.
Undersøgelsen viste også, at virkningen holdt sig i op til 52 uger, hvor Entyvio stadig virkede bedre end placebo.
Similarly, in this study the maintenance of the effect up to 52 weeks with Entyvio was more effective than with placebo.
Undersøgelsen viste, at børn, der fik Strensiq, fik forbedret strukturen af deres led, således som dette fremgik af røntgenbilleder, og størstedelen syntes at opnå højdevækst.
This study showed that children given Strensiq had an improvement in their joint structure as demonstrated by x-rays and most of them seemed to gain in height.
Undersøgelsen viste, at Daronrix med 15 mikrogram hæmagglutinin og adjuvans bevirkede en anti- stofrespons, der opfylder disse kriterier.
The study showed that Daronrix containing 15 micrograms of haemagglutinin and the adjuvant produced an antibody response that satisfies these criteria.
Undersøgelsen viste, at en enkelt 150 mg-infusion af Ivemend var lige så effektiv som et tredages forløb med Emend til at forebygge kvalme og opkastning.
The study showed that a single 150 mg infusion of Ivemend was as effective as a three-day course of Emend in preventing nausea and vomiting.
Undersøgelsen viste, at hos 15 % af de patienter, der fik Signifor i en dosis på 0,6 mg (12 patienter ud af 82), og 26 % af de patienter, der fik Signifor i en dosis på 0,9 mg (21 patienter ud af 80), blev kortisolindholdet i urinen normalt i løbet af seks måneder.
The study showed that 15% of patients receiving 0.6 mg Signifor (12 patients out of 82) and 26% of patients receiving 0.9 mg Signifor (21 patients out of 80) had normal urine cortisol levels within six months.
Undersøgelsen viste, at NexoBrid var mere effektivt end standardbehandling (kirurgisk og ikke- kirurgisk) til at mindske andelen af de dybe delhudsforbrændinger, der krævede operativ fjernelse af hudvæv eller hudtransplantation.
The study showed that NexoBrid was more effective than standard of care treatment (surgical and non-surgical) at reducing the proportion of the deep partial thickness burn wounds that needed surgery to remove skin tissue or required a skin graft.
Undersøgelsen viste, at sygdommen efter et år havde holdt sig stabil hos 85 % af de patienter, der blev behandlet med Cerdelga, sammenholdt med 94 % af dem, der fortsatte med enzymerstatning.
This study found that, after treatment for a year, the disease remained stable in 85% of patients treated with Cerdelga compared with 94% of patients who continued with the enzyme replacement therapy.
Undersøgelsen viste, at tilføjelse af Empliciti til de to andre lægemidler forlængede den gennemsnitlige tid til sygdomsforværring fra 14,3 måneder til 18,5 måneder.
In this study, adding Empliciti to the two other medicines extended the average time before the disease got worse from 14.3 months to 18.5 months.
Undersøgelsen viste, at Vantobra kan anses for at svare til Tobi.
The results of the study showed that Vantobra can be considered comparable to Tobi.
Undersøgelsen, der sammenlignede Velcade givet henholdsvis under huden og i en vene, viste, at andelen af patienter, der responderede delvist eller fuldstændigt på behandlingen, var den samme (42 %) uanset administrationsmetoden.
The study that compared Velcade given under the skin with Velcade given into a vein showed that the percentage of patients who responded partially or completely to treatment was the same (42%) when using either route of administration.
Undersøgelsens primære effektmål var recidivfri overlevelse (RFS), defineret som tiden fra dato for randomisering til dato for tilbagefald eller død uanset årsag.
The primary endpoint of the study was recurrence-free survival (RFS), defined as the time from date of randomisation to the date of recurrence or death from any cause.
Undersøgelsens primære effektvariable var graden af det cytogenetiske hovedrespons (fuldstændigt plus partielt respons, 0–35% Ph+- metafaser i knoglemarven).
The primary efficacy variable of the study was the rate of major cytogenetic response (complete plus partial response, 0 to 35% Ph+ metaphases in the bone marrow).
Undersøgelsens resultater er summerede i Tabel 8.
The study results are summarized in Table 8.
Undersøgelser
/Frequency
Undersøgelser
Abdominal pain
Undersøgelser
activated partial
Undersøgelser
Adverse reaction
Undersøgelser
Back pain
Undersøgelser
Common
Undersøgelser
disorders
Undersøgelser
Dizziness
Undersøgelser
Elderly
Undersøgelser
fraction
Undersøgelser
Hypertension
Undersøgelser
Increased total bilirubin
Undersøgelser
Investiga tions
Undersøgelser
Investigati ons
Undersøgelser
Investigatio ns
Undersøgelser
Respiratory disorder
Undersøgelser
Uncommon
Undersøgelser (Almindelig, ≥ 1 % til < 10 %)
Investigations (Common, ≥1/100 to <1/10)
Undersøgelser (fund baseret på testresultater præsenteret som skift af CTCAE-grad)
Investigations (findings based on test results presented as CTCAE grade shifts)
Undersøgelser af aliskiren-monoterapi har vist en blodtrykssænkende effekt, som er sammenlignelig med andre klasser af antihypertensive lægemidler, herunder ACE-hæmmere og angiotension-II- antagonister.
Aliskiren monotherapy studies have shown blood-pressure-lowering effects comparable to other classes of antihypertensive medicinal products including selected ACEI and ARB.
Undersøgelser af binding viser, at agomelatin ikke påvirker optagelsen af monoamin og ikke har affinitet til -, -adrenerge, histaminerge, kolinerge, dopaminerge og benzodiazepinreceptorer.
Binding studies indicate that agomelatine has no effect on monoamine uptake and no affinity for ,  adrenergic, histaminergic, cholinergic, dopaminergic and benzodiazepine receptors.
Undersøgelser af cerebrospinalvæske er ofte positive for pleocytose med op til flere tusinde celler pr. mm3, hovedsageligt fra den granulocytiske serie, og et forhøjet proteinniveau på op til flere hundrede mg/dl.
Cerebrospinal fluid studies are frequently positive with pleocytosis up to several thousand cells per mm3, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL.
Undersøgelser af din hud før, under og efter behandling
Checks of your skin before, during and after treatment
Undersøgelser af filgrastim hos patienter med stærkt nedsat nyre- eller leverfunktion viser, at filgrastim har en farmakokinetisk og farmakodynamisk profil, som ligner den, man ser hos raske personer.
Studies of filgrastim in patients with severe impairment of renal or hepatic function demonstrate that it exhibits a similar pharmacokinetic and pharmacodynamic profile to that seen in normal individuals.
Undersøgelser af humane levermikrosomer viste, at artenimol blev metaboliseret af UDP-glukuronosyltransferase (UGT1A9 og UGT2B7) til α-artenimol-G uden en cytokrom P450-medieret metabolisme.
Studies in human liver microsomes showed that artenimol was metabolised by the UDP-glucuronosyltransferase (UGT1A9 and UGT2B7) to α- artenimol-G with no cytochrome P450-mediated metabolism.
Undersøgelser af hvalpe har dokumenteret ledskader efter brug af orbifloxacin givet via munden eller ved injektion.
Laboratory studies in puppies have shown evidence of arthropathy after systemic administration of orbifloxacin.
Undersøgelser af Rasilez-monoterapi har vist en blodtrykssænkende effekt, som er sammenlignelig med andre klasser af antihypertensiva, herunder ACE-hæmmere og angiotension-II-antagonister.
Rasilez monotherapy studies have shown blood pressure lowering effects comparable to other classes of antihypertensive agents including ACEI and ARB.
Undersøgelser af serumjerndepotparametre har vist, at der er en lav systemisk absorption af jern på cirka 1 % fra Fexeric.
Examination of serum iron storage parameters has shown that there is low systemic absorption of iron of approximately 1% from Fexeric.
Undersøgelser af sitagliptin i kombination med metformin
Studies of sitagliptin in combination with metformin
Undersøgelser af toksicitet ved gentagne doser har vist, at niveauer op til 200 mg/kg/dag er veltolererede i rotter; hunde er tilsyneladende mere sensitive, sandsynligvis grundet hundes høje følsomhed for ulcerogene effekter af NSAID’er.
Repeat-dose toxicity studies have shown that levels up to 200 mg/kg/day are well tolerated in rats; dogs appear to be more sensitive, probably due to the high sensitivity of canines to the ulcerogenic effects of NSAIDs.
Undersøgelser af udvikling af fostre og den pre- og postnatale udvikling viste øjenmisdannelser, skeletanomalier, aborter og forhøjet hyppighed af fosterdød.
Studies on embryofoetal development and pre-and postnatal development revealed eye malformations, skeletal anomalies, abortions, and an increased foetal death rate.
Undersøgelser for blødning i fordøjelsessystemet
Checks for digestive bleeding
Undersøgelser Forhøjet blodkreatinin
Investigations Blood creatinine increased
Undersøgelser forhøjet legemstemperatur, øget behov for katekolaminer til at understøtte blodtrykket i behandlingsforløbet.
Investigations increased body temperature, increased need of catecholamines to support blood pressure (verbatim term: increased need for catecholamines) in the course of the treatment.
Undersøgelser forøget C-reaktivt protein
Investigations increased C-reactive protein
Undersøgelser h
Investigationsh
Undersøgelser har vist at månedlig behandling af hunde vil forebygge infektioner forårsaget af
Studies have shown that monthly treatment of dogs will prevent infections caused by Uncinaria stenocephala.
Undersøgelser har vist en øget risiko for fødselsskader hos børn af kvinder, som har taget antieleptisk medicin.
Research has shown an increased risk of birth defects in children of women taking anti-epileptic medicines.
Undersøgelser har vist sig at være fordelagtige ved to former for NSCLC, kendt som ikke-squamøs og squamøs.
Studies have shown benefit in two forms of NSCLC, known as non-squamous and squamous.
Undersøgelser har vist, at cidofovir er klastogenetisk in vitro ved 100 µg/ml og embryotoksisk hos rotter og kaniner.
Studies have shown that cidofovir is clastogenic in vitro at 100 µg/ml and is embryotoxic in rats and rabbits.
Undersøgelser har vist, at indgivelse sammen med lutropin alfa ikke signifikant ændrer aktivitet, stabilitet, farmakokinetik eller de farmakokinetiske egenskaber af de aktive stoffer.
Studies have shown that co-administration with lutropin alfa, does not significantly alter the activity, stability, pharmacokinetic nor pharmacodynamic properties of the active substances.
Undersøgelser hos patienter med nedsat nyrefunktion viser, at eliminationen af lamivudin påvirkes ved dysfunktion af nyrerne.
Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction.
Undersøgelser i laboratorier af, hvor sikkert lægemidlet er, viste ikke tegn på interaktion, når sarolaner blev givet samtidigt med milbemycinoxim, moxidectin og pyrantelpamoat. (I disse undersøgelser effekt ikke blev undersøgt.)
In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate. (In these studies efficacy was not investigated).
Undersøgelser Ikke almindelig Forhøjet alaninaminotransferase, forhøjet aspartataminotransferase
Investigations Uncommon Alanine aminotransferase increased, aspartate aminotransferase increased
Undersøgelser in vitro af emedastins affinitet til histamin receptorerne (H1, H2 og H3) viser En 10.000-gang højere selektivitet for H1 receptoren.
In vitro examinations of emedastine’s affinity for histamine receptors (H1, H2, and H3) demonstrate
Undersøgelser in vitro af emedastins affinitet til histaminreceptorerne (H1, H2 og H3) viser en 10.000-gang højere selektivitet for H1 receptoren med henholdsvis Ki = 1.3 nM, 49.064 nM og
In vitro examinations of emedastine’s affinity for histamine receptors (H1, H2, and H3) demonstrate
Undersøgelser inden behandlingsstart og anbefalede kontrolundersøgelser og forsigtighedsregler
Before the start of treatment and recommended follow-up examinations and precautions
Undersøgelser kan vise: lavt antal blodplader, lavt antal hvide blodlegemer (neutropeni), blodmangel, væske omkring lungerne
Tests may show: low blood platelet count, low white blood cells count (neutropaenia), anaemia, fluid around the lungs
Undersøgelser kan vise: unormale blodprøveresultater og risiko for nedsat nyrefunktion på grund af affaldsstoffer fra den døende svulst (tumorlysesyndrom), lavt indhold af albumin i blodet, lavt indhold af lymfocytter (en slags hvide blodceller), højt indhold af kolesterol i blodet, hævede lymfekirtler, blødninger i hjernen, forstyrrelser i hjertets elektriske aktivitet, forstørret hjerte, leverbetændelse, protein i urinen, forhøjet kreatinkinase (et enzym, der hovedsageligt findes i hjertet, hjernen og skeletmusklerne), forhøjet troponin (et enzym, der hovedagligt findes i hjerte- og skeletmuskulaturen), forhøjet gamma-glutamyltransferase (et enzym, der hovedsageligt findes i leveren)
Tests may show: abnormal blood test results and possibly impaired kidney function caused by the waste products of the dying tumour (tumour lysis syndrome), low levels of albumin in the blood, low levels of lymphocytes (a type of white blood cell) in the blood, high level of cholesterol in the blood, swollen lymph nodes, bleeding in the brain, irregularity of the electrical activity of the heart, enlarged heart, inflammation of the liver, protein in the urine, raised creatine phosphokinase (an enzyme mainly found in the heart, brain and skeletal muscles), raised troponin (an enzyme mainly found in the heart and skeletal muscles), raised gamma-glutamyltransferase (an enzyme mainly found in the liver)
Undersøgelser med flere typer af infusionsslanger fremstillet af polyvinylklorid, polyethylen og polypropylen viste ingen uforligelighed med zoledronsyre.
Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with zoledronic acid.
Undersøgelser med forskellige typer af infusionsslanger fremstillet af polyvinylklorid, polyethylen og polypropylen viste ingen uforligelighed med Zoledronsyre Accord.
Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with Zoledronic Acid Accord.
Undersøgelser med forskellige typer af infusionsslanger fremstillet af polyvinylklorid, polyethylen og polypropylen viste ingen uforligelighed med Zoledronsyre Teva.
Studies several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with zoledronic acid.
Undersøgelser med forskellige typer af infusionsslanger fremstillet af polyvinylklorid, polyethylen og polypropylen viste ingen uforligelighed med Zoledronsyre Teva.
Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with Zoledronic acid Teva.
Undersøgelser med forskellige typer infusionsslanger fremstillet af polyvinylklorid, polyethylen og polypropylen viste ingen uforligelighed med Zoledronsyre Hospira.
Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with zoledronic acid.
Undersøgelser med in vitro-plasmaproteinbinding viste at den gennemsnitlige koncentration af fri aktiv substans var 74%.
In vitro plasma protein binding studies determined that the mean concentration of the free active substance was 74 %.
Undersøgelser med kombinationer af dextromethorphan/kinidin i højere dosering
Studies with Higher Dose Combinations of dextromethorphan / quinidine
Undersøgelser med laboratoriedyr har imidlertid vist embryofoetotoksicitet, misdannelser, forsinket fødsel og nedsat overlevelse af det nyfødte dyr.
However, studies with laboratory animals have shown embryo- foetotoxicity, malformations, delayed parturition and decreased pup survival.
Undersøgelser med laboratoriedyr har imidlertid vist embryoføtotoksicitet, misdannelser, forsinket fødsel og nedsat overlevelse af det nyfødte dyr.
However, studies with laboratory animals have shown embryo-foetotoxicity, malformations, delayed parturition and decreased pup survival.
Undersøgelser med mannitol administreret peroralt viste imidlertid ingen teratogen virkning hos mus eller rotter ved doser på op til 1,6 g/kg eller hos hamstere ved 1,2 g/kg.
However, studies conducted with orally administered mannitol indicated no teratogenic effects in mice or rats, at doses of up to 1.6 g/kg, or in hamsters at 1.2 g/kg.
Undersøgelser med mannitol administreret via andre veje viste imidlertid ingen virkning på fosteroverlevelsen hos mus, rotter og hamstere og på fosterudviklingen hos rotter og kaniner.
However, studies conducted with mannitol administered via other routes indicated no effect on foetal survival in mice, rats and hamsters and on embryo and foetal development in rats and rabbits.
Undersøgelser med rotter og mus har ikke vist tegn på teratogenicitet, men sikkerhedsprofilen af stoffet hos drægtige og diegivende søer er ikke blevet undersøgt.
Whilst studies in rats and mice have not produced any evidence of teratogenic effect, the safety in pregnant and lactating sows and does has not been established.
Undersøgelser med rotter, mus og mennesker har vist, at mannitol ikke har toksiske metabolitter.
Studies in rats, mice and humans have demonstrated that mannitol has no toxic metabolites.
Undersøgelser på andre former for operationer end CABG omfatter kun patienter med ASA (American Society of Anaesthesiology) Physical Status klasse I-III.
Studies in types of surgery other than CABG procedures included patients with ASA (American Society of Anaesthesiology) Physical Status Class I-III only.
Undersøgelser på dyr og klinisk erfaring har påvist, at buprenorphin kan forårsage afhængighed, men i ringere grad end en ren agonist som morphin.
Studies in animals, as well as clinical experience, have demonstrated that buprenorphine may produce dependence, but at a lower level than a full agonist e.g. morphine.
Undersøgelser på grise viser, at applikation af von Willebrand Factor (WF, 66 IE/kg legemsvægt.) tydeligt reducerer blødningstiden.
Results from studies in pigs showed that the application of von Willebrand Factor (vWF, 66 I.U./kg body weight) markedly reduced the bleeding time.
Undersøgelser på laboratoriedyr har ikke vist nogen negativ indflydelse på udvikling eller reproduktion.
Based on laboratory animal data, gamithromycin has not produced any evidence of selective developmental or reproductive effects.